ADVANCES IN Cancer IMMUNOTHERAPY™

Mechanisms of Immune-Related Adverse Events

Diwakar Davar
Melanoma and Phase I Therapeutics
University of Pittsburgh Medical Center

AMERICAN ACADEMY OF EMERGENCY MEDICINE

ACCC
Association of Community Cancer Centers

sitc
Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Disclosures

- Advisory Board: Incyte
- Research Support: Bristol-Myers Squibb, Merck, Incyte, Checkmate Pharmaceuticals
- I will not be discussing non-FDA approved indications during my presentation.

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Outline

- Basic principles of immunological tolerance and autoimmunity
- Differential roles of CTLA-4 and PD-1 in maintenance of tolerance
- Mechanisms of breakdown of tolerance by checkpoint blockade

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

Major Effector Cells of the Immune System



ADVANCES IN Cancer IMMUNOTHERAPY™

Most Autoimmune Diseases are due to Failure of T cell Tolerance

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

As a reminder…



MHC = Major Histocompatibility Complex

also called the HLA (human leukocyte antigen) complex

ACCC Association of Community Cancer Centers

sitc Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

HLA (or MHC) is the strongest genetic factor for susceptibility to autoimmune disease

HLA- and gender-associated risk for autoimmune disease			
Disease	**HLA allele**	**Relative risk**	**Sex ratio (♀:♂)**
Ankylosing spondylitis	B27	87.4	0.3
Type 1 diabetes	DQ2 and DQ8	~25	~1
Goodpasture's syndrome	DR2	15.9	~1
Pemphigus vulgaris	DR4	14.4	~1
Autoimmune uveitis	B27	10	<0.5
Psoriasis vulgaris	CW6	7	~1
Systemic lupus erythematosus	DR3	5.8	10–20
Addison's disease	DR3	5	~13
Multiple sclerosis	DR2	4.8	10
Rheumatoid arthritis	DR4	4.2	3
Graves' disease	DR3	3.7	4–5
Hashimoto's thyroiditis	DR5	3.2	4–5
Myasthenia gravis	DR3	2.5	~1
Type I diabetes	DQ6	0.02	~1

Figure 15.37 Janeway's Immunobiology, 9th ed. (© Garland Science 2017)

Central and Peripheral Tolerance



Central Tolerance

- For T cells it occurs in the thymus
- Fate of high affinity, self-reactive T cells is death (deletion) and removal from T cell pool
- Some survive as regulatory (suppressor) T cells while others escape to peripheral tissues

Peripheral Tolerance

- Self-reactive T cells are suppressed by regulatory T cells
- CTLA-4 and PD-1, among other molecules play a role in maintaining self-reactive T cells from becoming activated (anergic)

Peripheral tolerance occurs in the absence of CD28 dependent co-stimulation



CTLA-4 inhibits co-stimulation by blocking interaction between CD28 and B7 molecules





Anti-CTLA-4 can lead to breakdown of peripheral tolerance by restoring co-stimulation





Breakdown of peripheral tolerance leading to activation of self-reactive T cells

Regulatory T cells (Tregs) use CTLA-4 to remove B7 molecules from surface of antigen presenting cells to prevent activation of self reactive T cells



Anti-CTLA-4 (ipilimumab) may interfere with inhibitory function of Tregs

Inhibitory receptors provide a second mechanism for maintenance of tolerance



Interaction of PD-1 with its ligands, PD-L1/PD-L2 inhibits CD28 signaling in T cells

- PD-1 is upregulated on T cells after activation
- PD-L1 is found on both immune and non-immune cells in peripheral tissues
- PD-L2 is mostly found on immune cells in response to inflammatory stimuli
- In contrast, CTLA-4 and its ligands are only found on immune cells
- Mice deficient in PD-1 have delayed development of autoimmune disease compared to CTLA-4 deficient ones



Blocking PD-1/PD-L1 Pathway Reactivates T cells

PD-1 is the receptor on T cells – its ligand PD-L1 is on immune cells or tumor cells



Polymorphisms in CTLA-4 and PD-1 genes have been linked to human autoimmune diseases

Autoimmune Disease	Polymorphism
Thyroiditis, Graves' disease, Hashimoto's disease	CTLA-4
Diabetes mellitus	CTLA-4
Celiac disease	CTLA-4
Myasthenia gravis	CTLA-4
Lupus	CTLA-4; PD-1
Rheumatoid Arthritis	CTLA-4; PD-1
Addison's disease	CTLA-4

Adapted from Michot JM, *et al* ; *European Journal of Cancer*; 2016; **54**:139

People with CTLA-4 haploinsufficiency develop a spectrum of autoimmune diseases similar to the irAEs observed with ipilimumab

CHAI/LATAIE Phenotype



Lo, B. *et al* ; *Blood*; 2016; **128**:1037

Ipilimumab irAEs



Michot JM, *et al* ; *European Journal of Cancer*; 2016; **54**:139

Incidence of irAEs with PD-1, CTLA-4 and PD-1/CTLA-4 (Melanoma)

Select Treatment-Related AEs, %	Nivo + Ipi (n = 313)		Nivo (n = 313)		Ipi (n = 311)	
	All Grades	Grade 3/4	All Grades	Grade 3/4	All Grades	Grade 3/4
Any select AE	88	40	62	8	74	19
Skin	59	6	42	2	54	3
▪ Pruritus	33	2	19	0	35	< 1
▪ Rash	28	3	22	< 1	21	2
▪ Maculopapular rash	12	2	4	< 1	12	< 1
Gastrointestinal	46	15	20	2	37	12
▪ Diarrhea	44	9	19	2	33	6
▪ Colitis	12	8	1	< 1	12	9
Hepatic	30	19	6	3	7	2
▪ ALT increase	18	8	4	1	4	2
▪ AST increase	15	6	4	1	4	< 1
Endocrine	30	5	14	< 1	11	2
▪ Hypothyroidism	15	< 1	9	0	4	0
Pulmonary	7	1	2	< 1	2	< 1
▪ Pneumonitis	6	1	1	< 1	2	< 1

Larkin J, NEJM 2015 (CheckMate 067)

Timing of irAEs with PD-1, CTLA-4 and PD-1/CTLA-4 (Melanoma)



Hassel JC, Cancer Treatment Rev 2017

Early and late irAEs may occur by distinct mechanisms

Early and common

Mucosal
Colitis
Rash
Pneumonitis

Global Regulatory T cell dysfunction

↓

Activation of Effector T cells (Th_{17})

↓

Recruitment of inflammatory cells (neutrophils)

Late and rare

Specific organ
Hypophysitis
(other endocrine)
Myocarditis; Neurologic
Arthritis; Vitiligo

Breakdown of organ specific tolerance

↓

Activation of tumor specific T cells that recognize antigen shared between tumor and healthy tissue: vitiligo, myocarditis

Activation of tissue specific anergic T cells that recognize antigen distinct from the tumor

T cell or antibody mediated tissue destruction

CTLA-4 Expression in Pituitary Gland → Ipilimumab-related Hypophysitis



Metastatic melanoma s/p Nivolumab x26 cycles





Following 2 weeks of steroids …





Summary: CTLA-4 and PD-1 are important in maintenance of peripheral immune tolerance

- CTLA-4 expression on effector and regulatory T cells prevents co-stimulation through CD28 and maintains T cell anergy and peripheral tolerance
- Interaction between PD-1 ad PD-L1/L2 renders activated T-cells non-functional
  - PD-1 activates regulatory T cells to maintain peripheral tolerance
- Humans with CTLA-4 haploinsufficiency develop a spectrum of autoimmune manifestations similar to irAEs seen after treatment with Ipilimumab

Summary: Mechanisms of IRAE

- IRAEs can be thought of as “early/common” (mucosal) and “late/rare” (organ-specific) with distinct MOA.
  - Mucosal: effects on Treg function
  - Organ specific: loss of organ-specific tolerance
- IRAEs can be severe
- Early recognition of IRAEs critical to defining optimal management